Vancouver, Kelowna and Delta, British Columbia--(Newsfile Corp. - July 11, 2024) - Investorideas.com, a go-to investing platform releases the first of a two-part series looking at transformative innovation in biopharma, featuring Citius Pharmaceuticals, Inc. (NASDAQ: CTXR), a late-stage biopharmaceutical company dedicated to the development and commercialization of first-in-class critical care products. The Company's diversified pipeline includes two late-stage product candidates.Read the full article on I ...

Multiple catalysts for potentially transformative assets in second half of 2024Strong momentum expected from positive topline results of Phase 3 Mino-Lok® trial, commercialization of LYMPHIR™ if approvedFirst-and-only advantage for Mino-Lok with no current FDA-approved or investigational products; LYMPHIR expected to be additive to current treatment options with mechanism of action supporting market advantageFinancial platform and pending oncology spin-off support pipeline development and investment in long ...

Management call scheduled for Monday, June 3, 2024 at 8:30 AM ET CRANFORD, N.J., May 29, 2024 /PRNewswire/ -- Citius Pharmaceuticals, Inc. ("Citius" or the "Company") (Nasdaq: CTXR), a late-stage biopharmaceutical company dedicated to the development and commercialization of first-in-class critical care products, today announced that it will host an investor call on Monday, June 3, 2024 at 8:30 am ET to discuss the topline results of its Phase 3 Trial of Mino-Lok antibiotic lock solution. Citius Chairman an ...

文章核心观点 - Citius Pharmaceuticals公司的抗生素锁定溶液Mino-Lok在III期临床试验中达到了主要和次要终点 [1][2][3] - Mino-Lok可能成为治疗中心静脉相关感染或导管相关血流感染的新标准治疗方案,提供了一种非侵入性的治疗选择 [3] - Citius Pharmaceuticals公司股票当日交易量大幅增加,股价上涨10.5%,但仍较年初下跌10.2% [3] 公司情况 - Citius Pharmaceuticals公司是一家制药公司,专注于开发Mino-Lok这款抗生素锁定溶液 [1][2][3] - Mino-Lok用于治疗中心静脉相关感染或导管相关血流感染 [2][3] 临床试验结果 - Mino-Lok在III期临床试验中达到了主要终点,即延长导管失效时间,对照组导管中位失效时间为33天,而Mino-Lok组超出了试验时间 [3] - Mino-Lok还达到了次要终点 [2][3]

Trial achieves statistically significant primary endpoint (p=0.0006) Secondary endpoint demonstrates statistically significant overall success of Mino-Lok therapy with a greater percentage of patients retaining their catheters (p=0.0025) CRANFORD, N.J., May 21, 2024 /PRNewswire/ -- Citius Pharmaceuticals, Inc. ("Citius" or the "Company") (Nasdaq: CTXR), a late-stage biopharmaceutical company dedicated to the development and commercialization of first-in-class critical care products, today announced positive ...

Citius Pharma (NASDAQ:CTXR) just reported results for the second quarter of 2024. Citius Pharma reported earnings per share of -5 cents. This met the analyst estimate for EPS of -5 cents. The company did not report any revenue for the quarter. InvestorPlace Earnings is a project that leverages data from TradeSmith to automate coverage of quarterly earnings reports. InvestorPlace Earnings distills key takeaways including earnings per share and revenue, as well as how a company stacks up to analyst estimates. ...

Exhibit 99.1 Citius Pharmaceuticals, Inc. Reports Fiscal Second Quarter 2024 Financial Results and Provides Business Update Mino-Lok data analysis on track with topline results anticipated this quarter LYMPHIR biologics license application accepted with PDUFA target action date set for August 13, 2024 CRANFORD, N.J., May 14, 2024 -- Citius Pharmaceuticals, Inc. (“Citius” or the “Company”) (Nasdaq: CTXR), a late-stage biopharmaceutical company dedicated to the development and commercialization of first-in-cl ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended: March 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ______________ to ______________ Commission File Number 001-38174 Citius Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Nevada ...

CRANFORD, N.J., May 10, 2024 /PRNewswire/ -- Citius Pharmaceuticals, Inc. ("Citius" or the "Company") (Nasdaq: CTXR), a late-stage biopharmaceutical company dedicated to the development and commercialization of first-in-class critical care products, today announced its participation in two upcoming investor conferences. Citius Chairman and CEO Leonard Mazur will host one-on-one investor meetings at the EF Hutton Annual Global Conference on May 15, 2024, and present and host one-on-one investor meetings at t ...

公司发行 - Citius Pharmaceuticals Inc.宣布将以每股$0.70的价格购买21,428,574股普通股和相应的认股权证[1] - 本次发行预计将为公司带来约1500万美元的募集资金，用于一般企业用途[2] - 本次发行是根据SEC于2024年2月23日提交的“Shelf”注册声明进行的[3] 公司背景 - Citius Pharmaceuticals Inc.是一家专注于开发和商业化首创重症护理产品的晚期生物制药公司[6]